NASDAQ · Medical - Devices

LUCD (LUCD) Stock

$0.97 +1.47% NASDAQ: LUCD Healthcare

Valuation

MetricValue
Price$0.97
Market Cap$98.94M
P/E Ratio-1.45
P/B Ratio9.30
P/S Ratio19.93
EPS (TTM)$-0.69
52-Week High$1.63
52-Week Low$0.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-527.27%
ROA-145.00%
ROCE-500.00%
Gross Margin-980.00%
Operating Margin-1000.00%
Net Margin-8.77%
Debt/Equity6.70
Current Ratio1.28

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$2.0M$4.0M$5.0M
Operating Profit$-27.0M$-56.0M$-48.0M$-46.0M$-50.0M
Net Profit$-28.0M$-56.0M$-53.0M$-46.0M$-58.0M
EPS$-0.78$-1.55$-1.26$-1.05$-0.69
Op Margin-5483.8%-14899.5%-1996.8%-1059.6%-1054.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$59.0M$33.0M$27.0M$31.0M$40.0M
Total Liabilities$4.0M$9.0M$30.0M$25.0M$30.0M
Cash$54.0M$22.0M$19.0M$22.0M$35.0M
Borrowings$0$2.0M$15.0M$21.0M$26.0M

Latest News

Why Lucid Diagnostics Inc. (LUCD) Faced a Price Target Reduction After Q1 Results Insider Monkey · Jun 2, 2026 PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results PR Newswire · May 15, 2026 Lucid Diagnostics Inc (LUCD) Q1 2026 Earnings Call Highlights: Exceeding Test Targets and ... GuruFocus.com · May 14, 2026 Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary Moby · May 14, 2026 LUCD Q1 2026 Earnings Transcript Motley Fool · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-18.0M$-30.0M$-33.0M$-44.0M$-46.5B
Investing Cash Flow$-2.0M$-5.0M$0$-1.0M$-197.0M
Financing Cash Flow$-6.0M$1.0M$1.0M$0$59.0B
Net Cash Flow$54.0M$-31.0M$-4.0M$3.0M$12.3B
Free Cash Flow$-19.0M$-31.0M$-33.0M$-45.0M$-46.5B

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-45.39%
Quick Ratio1.03
Interest Coverage—
Return 1Y-13.25%
Return 3Y-23.68%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APYX $4.07 -1.21% -17.90 $171.39M 0.00%
AVR $8.28 +0.00% -2.56 $304.61M 0.00%
IRDOpus Genetics, Inc. $3.32 +7.63% -2.35 $273.71M 0.00%
IXHL $2.99 +1.19% -0.09 $35.71M 0.00%
OWLT $5.49 +6.71% -2.67 $99.25M 0.00%

About LUCD

LUCD is led by CEO Lishan Aklog, employs 72 people, headquartered in US, publicly traded since 2021.

LUCD stock trades at $0.97 with a market capitalization of $98.94M. The stock is valued at a price-to-earnings (P/E) ratio of -1.45, price-to-book of 9.30, price-to-sales of 19.93. Over the past 52 weeks the stock has ranged between $0.90 and $1.63, and currently trades 40.5% below its 52-week high.

On profitability, LUCD generates a return on equity (ROE) of -527.27%, return on capital employed of -500.00%, an operating margin of -1000.00%, a net profit margin of -8.77%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides